secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001193125-25-173575
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Personalis Reports Q2 2025 Revenue of $17.2M, Net Loss $20.1M; Clinical Test Volume Up 59% Sequentially
--------------------------------------------------------------------------------

- Delivered 3,478 clinical tests in Q2 2025, a 59% sequential increase over Q1 2025.
- Revenue decreased 24% to $17.2M from $22.6M in Q2 2024, partly due to $5.6M decline from Natera.
- Net loss was $20.1M ($0.23 per share) versus $12.8M ($0.24 per share) in Q2 2024.
- Expanded Tempus AI collaboration to include colorectal cancer for exclusive commercialization.
- Lowered full-year 2025 revenue guidance to $70-80M from $80-90M, citing biopharma headwinds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000119312525173575/0001193125-25-173575-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000119312525173575/d64395d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-173575

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer